| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. (ACRS) has 6 insiders with recent SEC Form 4 filings, including 17 buys and 0 sells. ACRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.95M | $66.85M | - | |
| Other | 510.0K | $2.44M | - | |
| COO | 336.3K | $1.61M | - | |
| CEO | 274.8K | $1.32M | - | |
| Other | 18.7K | $89.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 22, 2015 | Ra Capital Management, LLC53 | 10% Owner | Buy | 5,410 | $14.03 | $75,882.82 | +0.2% | |
| Oct 21, 2015 | Ra Capital Management, LLC53 | 10% Owner | Buy | 34,999 | $14.89 | $521,095.36 | +0.5% | |
| Oct 14, 2015 | Ra Capital Management, LLC53 | 10% Owner | Buy | 42,813 | $14.06 | $601,792.37 | +1.9% | |
| Oct 13, 2015 | Cha Albert | Director | Buy | 454,545 | $11.00 | $4,999,995.00 | +12.2% | |
| Oct 13, 2015 | Vivo Ventures Vii, LLC | 10% Owner | Buy | 454,545 | $11.00 | $4,999,995.00 | +12.2% | |
| Oct 13, 2015 | Mehra Anand | Director, 10% Owner | Buy | 409,090 | $11.00 | $4,499,990.00 | +21.8% | |
| Oct 13, 2015 | Sofinnova Venture Partners Viii, L.P. | 10% Owner | Buy | 409,090 | $11.00 | $4,499,990.00 | +21.8% | |
| Oct 13, 2015 | Fmr LLC72 | 10% Owner, See Remark 1 | Buy | 335,455 | $11.00 | $3,690,005.00 | +9.7% | |
| Oct 8, 2015 | Ra Capital Management, LLC53 | 10% Owner | Buy | 2,237,130 | $10.86 | $24,289,919.53 | +41.9% | |
| Oct 7, 2015 | Vivo Ventures Vii, LLC | 10% Owner | Buy | 13,352 | $11.00 | $146,872.00 | +4.6% |